Apollo Therapeutics Announces Second Close of Series C Financing
Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital
The Institute of Cancer Research, London, and biopharmaceutical company Apollo Therapeutics have announced a new collaboration that will advance the development of new cancer drugs, combining the strengths and expertise of both organisations.
Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development
Apollo Therapeutics has landed the rights to an immunology drug from Avalo Therapeutics to the tune of $15 million upfront and $74 million in milestones should the therapy make a series of small steps in the clinic.
Apollo Therapeutics has expanded its partnerships with world-leading UK research institutions, entering into a strategic collaboration with King’s College, London. King’s now joins Imperial College, UCL, and the University of Cambridge as one of Apollo’s top global research partners.
CAMBRIDGE, Mass. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Apollo Therapeutics, a biopharmaceutical company focused on translational biology and asset-centric drug development, and King’s College London, today announced the formation of a new strategic collaboration.
CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing transformative treatments based on breakthrough discoveries, today announced the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer. Dr. Aggarwal will be based in the company’s U.S. facility located at the Cambridge Innovation Center in Cambridge, Mass.